Health CareHealth Care Equipment & Services
  • Price (USD)184.86
  • Today's Change12.23 / 7.08%
  • Shares traded1.53m
  • 1 Year change-2.71%
  • Beta0.8525
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

  • Revenue in USD (TTM)4.35bn
  • Net income in USD1.05bn
  • Incorporated1999
  • Employees13.90k
  • Location
    Edwards Lifesciences Corp1 Edwards WayIRVINE 92614-5688United StatesUSA
  • Phone+1 (949) 250-2500
  • Fax+1 (302) 655-5049
  • Websitehttps://www.edwards.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Zimmer Biomet Holdings Inc7.98bn1.13bn18.52bn19.90k16.391.498.672.325.475.4738.6160.140.32740.98716.05401,115.604.641.455.281.6071.3070.7214.184.690.67967.540.398653.740.621511.30405.109.4616.051.76
ResMed Inc.2.78bn460.37m20.58bn7.24k44.839.1133.097.393.173.1419.2115.620.6783.395.50384,586.3011.2112.5812.6514.6958.9758.6716.5318.161.8510.130.365348.2611.3810.88-9.343.56-0.95818.16
DexCom, Inc.1.48bn101.10m23.34bn3.90k235.2726.45155.8015.811.081.0816.119.640.68485.575.75378,461.504.69-1.965.42-2.3164.0765.656.85-
Edwards Lifesciences Corp4.35bn1.05bn35.79bn13.90k34.908.7031.428.234.954.9320.4919.840.73621.798.69312,805.8017.7715.1920.9318.1174.3774.3924.1421.992.60--0.12530.0016.7913.3642.245.2924.33--
Baxter International Inc11.36bn807.00m39.90bn50.00k51.085.0524.973.511.541.9221.9915.570.67013.956.08227,240.004.829.525.8711.9942.2242.297.1916.391.8116.600.403424.492.371.17-40.0012.04-18.18-16.14
Boston Scientific Corporation10.74bn4.70bn42.24bn36.00k9.073.037.403.933.333.337.619.950.41642.326.25298,194.4018.237.3722.689.3170.3770.7943.7816.230.64123.000.4190.009.287.78193.02--16.44--
Intuitive Surgical, Inc.4.48bn1.38bn53.50bn7.33k39.706.4333.4811.9511.5411.5437.4871.240.50952.726.75611,315.9015.7215.1417.6016.9269.4569.3030.8529.353.95--0.000.0020.2516.0122.2426.9232.15--
Data as of --. Currency figures normalised to Edwards Lifesciences Corp's reporting currency: US Dollar USD

Institutional shareholders

34.97%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 201915.90m7.62%
BlackRock Fund Advisorsas of 31 Dec 201911.32m5.43%
SSgA Funds Management, Inc.as of 31 Dec 20198.92m4.28%
Fidelity Management & Research Co. LLCas of 31 Dec 20197.89m3.78%
Sands Capital Management LLCas of 31 Dec 20196.07m2.91%
Jennison Associates LLCas of 31 Dec 20194.89m2.35%
Capital Research & Management Co. (Global Investors)as of 31 Dec 20194.67m2.24%
Wellington Management Co. LLPas of 31 Dec 20194.46m2.14%
Capital Research & Management Co. (International Investors)as of 31 Dec 20194.46m2.14%
Walter Scott & Partners Ltd.as of 31 Dec 20194.35m2.09%
More ▼
Data from 31 Dec 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.